01530.HK
3SBio Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 16.24
−0.31%Aug 20, 2026, 17:16 UTC
3SBio Inc. announced its interim results for the six months ended June 2026, with net profit of RMB 1.147 billion, down 15.6% year-on-year.
Jul 21, 2026, 19:36 UTC
Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.
Jul 3, 2026, 08:52 UTC
The China National Medical Products Administration's Drug Evaluation Center accepted the marketing authorization application for semaglutide injection (weight loss indication) filed by Sansheng Mandi, a partner of Hybio Pharmaceutical.
Source: